Evidence map›Paper›PMID 23526308›Full record

ArticleInfection2014

Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.

P Lutz, M Parcina, I Bekeredjian-Ding, A Hoerauf, C P Strassburg, U Spengler

2 registry-linked trialsAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Infection, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02074280 phase4unknown statusnot on this map

Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial

TypeinterventionalSponsorShanghai Changzheng HospitalRan2013 to 2014Enrolled250ConditionsCirrhosisArmsrifaximin
NCT02190357 phase4unknown statusnot on this map

Rifaximin Reduces the Complications of Decompensated Cirrhosis

TypeinterventionalSponsorShanghai Changzheng HospitalRan2014 to 2019Enrolled200ConditionsCirrhosisArmsRifaximin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. DisseminatedIDCases · 2022
    Article
  2. Review
  3. Article
  4. Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

P LutzDepartment of Internal Medicine I, University of Bonn, Sigmund-Freud-Str. 25, 53129, Bonn, Germany, philipp.lutz@ukb.uni-bonn.de.
M Parcina
I Bekeredjian-Ding
A Hoerauf
C P Strassburg
U Spengler
University of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis. Recently, rifaximin, a non-absorbable antibiotic which is used to prevent recurrent hepatic encephalopathy, has been proposed as effective prophylaxis for SBP. Here, we present an unusual case of SBP under treatment with rifaximin. A 50-year-old woman with liver cirrhosis was admitted because of tense ascites and abdominal pain. She was under long-term oral prophylaxis with rifaximin due to hepatic encephalopathy. Paracentesis revealed SBP caused by Pasteurella multocida, which was sensitive to multiple antibiotics, including rifaximin. Treatment with ceftriaxone resulted in rapid resolution of the peritonitis and restoration of the patient. Since P. multocida is usually transmitted from pets, the patient's cat was tested and could be identified as the most likely source of infection. This case should elicit our awareness that uncommon pathogens and unusual routes of transmission may lead to SBP, despite antibacterial prophylaxis with non-absorbable antibiotics. Nevertheless, such infections may still remain sensitive to systemic therapy with conventional antibiotics.

Indexed as

Antibiotic ProphylaxisAnti-Infective AgentsCeftriaxoneFemaleHumansLiver CirrhosisMicrobial Sensitivity TestsMiddle AgedPasteurella InfectionsPasteurella multocidaPeritonitisRifamycinsRifaximinTreatment OutcomeAnti-Infective AgentsCeftriaxoneRifamycinsRifaximin

Identifiers

PMID23526308
OpenAlexW1989463325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.